肿瘤化疗相关性血小板减少症中医药防治专家共识

2021-05-25 中华中医药学会血液病分会 北京中医药

肿瘤化疗相关性血小板减少症(chemotherapy-related thrombocytopenia,CIT)为肿瘤化疗常见不良反应,发生率与肿瘤类型、治疗方案和化疗周期等密切相关。

中文标题:

肿瘤化疗相关性血小板减少症中医药防治专家共识

发布日期:

2021-05-25

简要介绍:

肿瘤化疗相关性血小板减少症(chemotherapy-related thrombocytopenia,CIT)为肿瘤化疗常见不良反应,发生率与肿瘤类型、治疗方案和化疗周期等密切相关。CIT不仅能导致化疗药物使用剂量降低或化疗时间延迟,从而降低肿瘤治疗效果,影响患者预后和生存质量。同时,因增加血小板输注与血小板刺激因子的临床应用,治疗费用大幅增加。因此,对存在出血高危因素的患者进行一、二级预防,有助于降低CIT发生率和严重程度。基于中医"治未病"与"既病防变"理论,中医药参与CIT全程治疗具有重要临床意义。由中华中医药学会血液病分会、中国中西医结合学会肿瘤专业委员会、北京中西医结合学会肿瘤专业委员会组织中医与中西医结合专家制订本共识,旨在为临床医师提供更合理的CIT诊疗方案,保障肿瘤化疗顺利实施,提升外周血血小板数值,改善CIT患者临床症状,从而提高生存质量。 

相关资料下载:
[AttachmentFileName(sort=1, fileName=肿瘤化疗相关性血小板减少症中医药防治专家共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=a04c41c00225a1a6, title=肿瘤化疗相关性血小板减少症中医药防治专家共识, enTitle=, guiderFrom=北京中医药, authorId=0, author=, summary=肿瘤化疗相关性血小板减少症(chemotherapy-related thrombocytopenia,CIT)为肿瘤化疗常见不良反应,发生率与肿瘤类型、治疗方案和化疗周期等密切相关。, cover=https://img.medsci.cn/2021114/1636012947939_1608702.jpg, journalId=0, articlesId=null, associationId=2103, associationName=中华中医药学会血液病分会, associationIntro=中华中医药学会血液病分会, copyright=0, guiderPublishedTime=Tue May 25 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">肿瘤化疗相关性血小板减少症(chemotherapy-related thrombocytopenia,CIT)为肿瘤化疗常见不良反应,发生率与肿瘤类型、治疗方案和化疗周期等密切相关。CIT不仅能导致化疗药物使用剂量降低或化疗时间延迟,从而降低肿瘤治疗效果,影响患者预后和生存质量。同时,因增加血小板输注与血小板刺激因子的临床应用,治疗费用大幅增加。因此,对存在出血高危因素的患者进行一、二级预防,有助于降低CIT发生率和严重程度。基于中医"治未病"与"既病防变"理论,中医药参与CIT全程治疗具有重要临床意义。由中华中医药学会血液病分会、中国中西医结合学会肿瘤专业委员会、北京中西医结合学会肿瘤专业委员会组织中医与中西医结合专家制订本共识,旨在为临床医师提供更合理的CIT诊疗方案,保障肿瘤化疗顺利实施,提升外周血血小板数值,改善CIT患者临床症状,从而提高生存质量。&nbsp;</span></p>, tagList=[TagDto(tagId=119, tagName=肿瘤), TagDto(tagId=282, tagName=化疗), TagDto(tagId=98115, tagName=化学疗法诱发的血小板减少症)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=98115, guiderKeyword=化学疗法诱发的血小板减少症, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=45011, appHits=233, showAppHits=0, pcHits=752, showPcHits=44778, likes=3, shares=30, comments=9, approvalStatus=1, publishedTime=Tue Nov 16 23:56:36 CST 2021, publishedTimeString=2021-05-25, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=FUNNYMAN, createdTime=Thu Nov 04 16:40:49 CST 2021, updatedBy=4754896, updatedName=小小医者, updatedTime=Sat Jan 06 18:00:28 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=肿瘤化疗相关性血小板减少症中医药防治专家共识.pdf)])
肿瘤化疗相关性血小板减少症中医药防治专家共识.pdf
下载请点击:
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1241050, encodeId=f90f1241050c3, content=很受启发, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3f35576026, createdName=ms5000000670105665, createdTime=Thu Aug 25 23:36:40 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210911, encodeId=ec2c121091140, content=学习了,很有启发, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3f35576026, createdName=ms5000000670105665, createdTime=Wed Apr 13 18:26:10 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207077, encodeId=4117120e07787, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae16241095, createdName=56446_2968, createdTime=Wed Mar 30 05:34:19 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193450, encodeId=91b711934500f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=469f6292645, createdName=3416293_4926, createdTime=Tue Feb 15 01:33:03 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192232, encodeId=73c11192232a5, content=谢谢哦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210309/8cdb67009a5a436cb10e54131a6d0023/05e8b899d2b749eeb9226d900f97d5f4.jpg, createdBy=9a4e5438173, createdName=王者的眼神, createdTime=Fri Feb 11 10:51:24 CST 2022, time=2022-02-11, status=1, ipAttribution=)]
    2022-08-25 ms5000000670105665

    很受启发

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1241050, encodeId=f90f1241050c3, content=很受启发, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3f35576026, createdName=ms5000000670105665, createdTime=Thu Aug 25 23:36:40 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210911, encodeId=ec2c121091140, content=学习了,很有启发, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3f35576026, createdName=ms5000000670105665, createdTime=Wed Apr 13 18:26:10 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207077, encodeId=4117120e07787, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae16241095, createdName=56446_2968, createdTime=Wed Mar 30 05:34:19 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193450, encodeId=91b711934500f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=469f6292645, createdName=3416293_4926, createdTime=Tue Feb 15 01:33:03 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192232, encodeId=73c11192232a5, content=谢谢哦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210309/8cdb67009a5a436cb10e54131a6d0023/05e8b899d2b749eeb9226d900f97d5f4.jpg, createdBy=9a4e5438173, createdName=王者的眼神, createdTime=Fri Feb 11 10:51:24 CST 2022, time=2022-02-11, status=1, ipAttribution=)]
    2022-04-13 ms5000000670105665

    学习了,很有启发

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1241050, encodeId=f90f1241050c3, content=很受启发, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3f35576026, createdName=ms5000000670105665, createdTime=Thu Aug 25 23:36:40 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210911, encodeId=ec2c121091140, content=学习了,很有启发, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3f35576026, createdName=ms5000000670105665, createdTime=Wed Apr 13 18:26:10 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207077, encodeId=4117120e07787, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae16241095, createdName=56446_2968, createdTime=Wed Mar 30 05:34:19 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193450, encodeId=91b711934500f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=469f6292645, createdName=3416293_4926, createdTime=Tue Feb 15 01:33:03 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192232, encodeId=73c11192232a5, content=谢谢哦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210309/8cdb67009a5a436cb10e54131a6d0023/05e8b899d2b749eeb9226d900f97d5f4.jpg, createdBy=9a4e5438173, createdName=王者的眼神, createdTime=Fri Feb 11 10:51:24 CST 2022, time=2022-02-11, status=1, ipAttribution=)]
    2022-03-30 56446_2968

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1241050, encodeId=f90f1241050c3, content=很受启发, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3f35576026, createdName=ms5000000670105665, createdTime=Thu Aug 25 23:36:40 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210911, encodeId=ec2c121091140, content=学习了,很有启发, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3f35576026, createdName=ms5000000670105665, createdTime=Wed Apr 13 18:26:10 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207077, encodeId=4117120e07787, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae16241095, createdName=56446_2968, createdTime=Wed Mar 30 05:34:19 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193450, encodeId=91b711934500f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=469f6292645, createdName=3416293_4926, createdTime=Tue Feb 15 01:33:03 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192232, encodeId=73c11192232a5, content=谢谢哦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210309/8cdb67009a5a436cb10e54131a6d0023/05e8b899d2b749eeb9226d900f97d5f4.jpg, createdBy=9a4e5438173, createdName=王者的眼神, createdTime=Fri Feb 11 10:51:24 CST 2022, time=2022-02-11, status=1, ipAttribution=)]
    2022-02-15 3416293_4926

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1241050, encodeId=f90f1241050c3, content=很受启发, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3f35576026, createdName=ms5000000670105665, createdTime=Thu Aug 25 23:36:40 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210911, encodeId=ec2c121091140, content=学习了,很有启发, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3f35576026, createdName=ms5000000670105665, createdTime=Wed Apr 13 18:26:10 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207077, encodeId=4117120e07787, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ae16241095, createdName=56446_2968, createdTime=Wed Mar 30 05:34:19 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193450, encodeId=91b711934500f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=469f6292645, createdName=3416293_4926, createdTime=Tue Feb 15 01:33:03 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1192232, encodeId=73c11192232a5, content=谢谢哦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210309/8cdb67009a5a436cb10e54131a6d0023/05e8b899d2b749eeb9226d900f97d5f4.jpg, createdBy=9a4e5438173, createdName=王者的眼神, createdTime=Fri Feb 11 10:51:24 CST 2022, time=2022-02-11, status=1, ipAttribution=)]
    2022-02-11 王者的眼神

    谢谢哦

    0